MOTS-C: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. MOTS-C is discussed here as a research compound and is not approved by Health Canada or the FDA for the research applications described in this guide.

Last updated: July 2026

---

MOTS-C is one of the newer and, in a real sense, one of the strangest compounds in this entire guide series — it’s encoded in mitochondrial DNA rather than the nuclear DNA that makes almost everything else in human biology, discovered barely a decade ago, and already the subject of genuine excitement and a fair amount of overstatement in equal measure. Getting the actual evidence picture right here means separating what’s genuinely known from what’s being claimed about it online — and, in this case, those two things have recently diverged in a specific, checkable way.

Quick Facts

Class	Mitochondrial-derived peptide (MDP)
Discovered	2015, University of Southern California
Primary research use	Metabolic flexibility, exercise performance, longevity-oriented protocols
Administration	Subcutaneous, pre-exercise or morning
Typical effective range (community-reported)	5mg, three times weekly
Evidence tier	Strong, growing preclinical base; Phase 1 human safety data for a related analog, not MOTS-C itself; no completed efficacy trials
Regulatory status	Not approved anywhere; removed from FDA Category 2 in April 2026 but not placed in Category 1, pending PCAC review

The Story So Far

MOTS-C’s discovery story is genuinely unusual among the compounds in this guide series. In 2015, researchers at the University of Southern California identified it as a peptide encoded not in nuclear DNA — the genome most biology operates from — but in mitochondrial DNA, specifically within the region coding for 12S ribosomal RNA. That’s a fundamentally different origin than any other compound covered here, and it means MOTS-C is released directly by the mitochondria themselves, in response to metabolic stress, functioning as a kind of distress signal that recalibrates cellular energy handling in response to conditions like exercise.

The compound most associated with MOTS-C’s real human trial history isn’t MOTS-C itself — it’s CB4211, an analog developed by Cohbar Inc., a biotechnology company that built a pipeline specifically around mitochondrial-derived peptides. CB4211 progressed through Phase 1a and Phase 1b human trials, generating genuine safety and tolerability data. As of the most reliable available information, no Phase 2 or Phase 3 trials for MOTS-C or any MOTS-C analog are currently registered, and the CB4211 program itself appears to have stalled after its Phase 1 results.

Here’s where it’s worth being direct about something you may encounter elsewhere: some recent online material claims MOTS-C has “entered Phase 2a human trials for prediabetes” in 2025 or 2026. We were unable to find this trial registered on ClinicalTrials.gov or referenced with any specific, checkable trial identifier or named sponsor — and it directly contradicts more specific, better-sourced material describing the actual current state of MOTS-C’s clinical pipeline as stalled at Phase 1, for an analog rather than the compound itself. This is worth treating with the same skepticism this guide series has applied to similar unverified trial claims for other compounds — a specific-sounding claim without a registry number attached is a pattern worth learning to recognize, not just for MOTS-C.

On the regulatory side, MOTS-C was among the group of peptides removed from FDA Category 2 in April 2026, as part of the same broader reclassification wave affecting BPC-157, TB-500, and others — but, as with those compounds, it wasn’t placed into Category 1, and it currently sits in the same unclassified gap pending the Pharmacy Compounding Advisory Committee’s July 2026 review.

What It Actually Does

MOTS-C activates AMPK — AMP-activated protein kinase, a cellular energy sensor that switches on when a cell’s energy reserves are running low. Once triggered, AMPK activation improves glucose uptake, promotes fat oxidation, and supports mitochondrial function generally. These are, notably, many of the same cellular adaptations that exercise itself produces, which is why MOTS-C is frequently described as an “exercise mimetic.” That’s a useful shorthand for the mechanism, but it’s worth being precise about what it means: MOTS-C may amplify the metabolic response to exercise when combined with it, rather than substituting for training altogether.

What the Research Shows

The evidence picture here follows a now-familiar pattern from elsewhere in this guide series: extensive and growing preclinical work, alongside a human evidence base that’s thinner than it might first appear, and easy to overstate if you’re not precise about what’s actually been shown.

The foundational preclinical work is genuinely strong. MOTS-C was first documented in a 2015 Cell Metabolism paper demonstrating significant effects on insulin resistance in mouse models. That initial finding has been extended by subsequent research confirming AMPK activation and metabolic improvements across multiple animal models. A 2025 study published in Frontiers in Physiology, from researchers at the University of Auckland, specifically found that MOTS-C helped restore mitochondrial respiration in a type 2 diabetic heart model — a genuinely current, peer-reviewed addition to the preclinical case, extending its relevance into cardiac metabolic dysfunction specifically.

Human evidence is correlational, not interventional. MOTS-C levels are consistently found to be lower in people with obesity, insulin resistance, and type 2 diabetes, and to decline with age — a pattern that supports the underlying biological rationale without constituting clinical trial evidence that administering MOTS-C produces a specific outcome in humans.

The one human interventional data point — CB4211’s Phase 1 program — studied a related analog, not MOTS-C itself, and Phase 1 trials are designed to establish safety and tolerability, not efficacy. What was found was a favorable tolerability profile with no serious adverse events reported — genuinely useful safety information, but not evidence that MOTS-C (or CB4211) produces the metabolic or longevity benefits it’s researched and marketed for.

The honest summary: MOTS-C rests on a compelling, actively growing preclinical foundation and a real biological rationale (declining levels correlating with metabolic disease and age), but — as of this writing — no completed human efficacy trial exists for MOTS-C itself, for any of its proposed uses.

How It Compares

MOTS-C sits alongside NAD+ in the longevity and cellular health category. For a full comparison, see our NAD+ guide. The short version: both compounds share the basic rationale of restoring something the body produces less of with age, both rest more on preclinical and correlational human data than completed injectable-intervention outcomes trials, and neither should be considered more clinically validated than the other despite their different mechanisms (NAD+ as a coenzyme supporting energy metabolism and DNA repair broadly; MOTS-C as a mitochondrial-derived peptide specifically activating AMPK).

Who Shouldn’t Use This

MOTS-C has no approved label, so there’s no official contraindications list. Based on the available literature:

• Diabetes or use of glucose-lowering medication. MOTS-C’s mechanism directly affects glucose metabolism and insulin sensitivity — genuinely useful for the research questions it’s studied for, but also a real reason anyone managing blood sugar with medication should monitor closely and involve a healthcare provider, given the potential for an additive glucose-lowering effect.
• Pregnancy or breastfeeding. No human safety data exists in this context.

Beyond these, no established absolute contraindications exist in the published literature — reflecting how early-stage the human evidence base is, not a confirmed absence of risk.

Common Myths, Addressed

“MOTS-C has entered Phase 2 human trials.” We could not verify this claim against any registered trial with a specific identifier, and it contradicts more detailed, better-sourced descriptions of the current pipeline. Treat specific-sounding trial claims for this compound the way you’d treat similar unverified claims elsewhere — skeptically, absent a checkable registry number.

“The CB4211 trial results validate MOTS-C’s safety and effects.” CB4211 is a related analog, not MOTS-C itself, developed by a separate company for its own specific pipeline. Its Phase 1 safety data is a reasonable, if indirect, positive signal — it isn’t direct evidence for MOTS-C as sold and used by researchers today.

“Since MOTS-C levels correlate with metabolic disease, supplementing it will reverse that disease.” Correlation between low levels and a condition doesn’t establish that restoring those levels treats the condition — this is a common leap in reasoning across longevity research generally, and it’s worth holding the distinction clearly here specifically.

What Researchers Are Actually Experiencing

MOTS-C is consistently reported as one of the better-tolerated compounds in this guide series, with injection site reactions being the most commonly noted effect and little else of substance beyond that.

Timing comes up constantly in community discussion, specifically pre-exercise administration — fifteen to thirty minutes before training — reflecting the compound’s proposed exercise-mimetic mechanism and the idea that its effects may be most relevant when paired with the metabolic demands of a training session. On rest days, morning administration is the standard community approach.

Cycling is treated as standard practice rather than optional, more so than for most compounds in this guide series — community protocols consistently describe running MOTS-C for 8 to 12 weeks followed by 4 to 8 weeks off, reflecting concern about diminishing returns from continuous AMPK pathway activation.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, and individual experience varies — worth remembering more than usual here, given how early-stage the actual human evidence is.

The Practical Basics

Research Ranges

Protocol	Research Range	Frequency
Standard	5mg	Three times weekly, pre-exercise where applicable
Lower dose	1–2mg	Daily, twice weekly, or three times weekly
Higher range	10mg	Three times weekly

5mg three times weekly is the most common community starting point. Some researchers prefer lower doses (1–2mg) taken more frequently — a reasonable approach, especially when starting out.

Worked Dose Math

At 20mg/mL (a 40mg vial — standard 3mL vial capacity — reconstituted with 2mL BAC water, leaving comfortable headroom):

• 5mg → 0.25mL → 25 units
• 10mg → 0.5mL → 50 units

At 40mg/mL (a 40mg vial reconstituted with 1mL BAC water, for a smaller draw volume):

• 5mg → 0.125mL → 12.5 units
• 10mg → 0.25mL → 25 units

The underlying rule: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe.

Vial Planning

A 40mg vial at 20mg/mL gives you 40mg total — likely the most practical vial size for most researchers, given how many standard-dose sessions it covers. At a steady 5mg per session, three times weekly (15mg/week), that’s roughly 2.5 to 3 weeks per vial. At the higher 10mg dose, three times weekly (30mg/week), that’s a little over a week per vial.

Reconstitution and Storage — The Short Version

MOTS-C reconstitutes with standard BAC water, refrigerates at 2–8°C, and should be used within 28 days. For the complete process, see our dedicated reconstitution and storage guide.

Sourcing

Nothing MOTS-C-specific beyond the general picture — see our full guide on reading a Certificate of Analysis and vetting a vendor.

Administration

Subcutaneous injection, pre-exercise (15–30 minutes before training) or morning on rest days. No fasting requirement.

Best Practices

• Build cycling into your protocol from the start — 8 to 12 weeks on, 4 to 8 weeks off is the community standard, not an optional add-on.
• Time administration around training if exercise performance or metabolic flexibility is your specific objective — this is where the exercise-mimetic mechanism is most directly relevant.
• Monitor blood sugar if you’re managing diabetes or using glucose-lowering medication, given the compound’s direct mechanism on glucose metabolism.
• Track your protocol from day one — dose, timing relative to exercise, and observed effects, at minimum.

Common Mistakes to Avoid

• Treating unverified “Phase 2 trial” claims as established fact — verify against an actual registry entry before accepting any specific clinical trial claim for this compound.
• Running continuously without cycling off, given the community-standard concern about diminishing AMPK-pathway returns over time.
• Confusing CB4211’s Phase 1 data with direct evidence for MOTS-C — they’re related but distinct compounds from different development programs.
• Not recording the reconstitution volume, turning every dose calculation into a guess.

What Happens If You Stop

There’s no dedicated discontinuation research for MOTS-C. Given that it’s understood as restoring a signal the body produces less of with age and under metabolic stress, rather than correcting a permanent change, the reasonable expectation is that any benefit would fade as MOTS-C levels return toward baseline after stopping — consistent with how it’s discussed for NAD+ elsewhere in this guide series. This is a reasonable inference from the compound’s framing, not a documented finding. The standard community cycling practice (8–12 weeks on, 4–8 weeks off) already builds planned discontinuation into typical use, rather than treating continuous use as the default.

What to Expect, Week by Week

• Weeks 1–2: No dramatic acute effect typically reported; tolerability is usually the main early observation.
• Weeks 3–8: For exercise-performance or metabolic-flexibility objectives, this is roughly the window community reports of noticeable change most commonly begin to appear, though this varies considerably by individual and training context.
• Weeks 8–12: Many community protocols conclude an “on” cycle in this window before the standard 4–8 week break.

Individual timelines vary substantially, and — given how early-stage the human evidence is — this pattern comes almost entirely from community report rather than trial data.

Combining With Other Compounds

Some community and vendor discussion explores MOTS-C alongside GHK-Cu, on the rationale that GHK-Cu’s anti-inflammatory activity complements MOTS-C’s metabolic mechanism, and alongside Tesamorelin specifically for visceral fat-focused protocols. These combinations rest on mechanistic plausibility (the compounds don’t obviously conflict) rather than any trial demonstrating a combined benefit — treat them as reasonable hypotheses worth your own careful research, not established stacking protocols.

Common Questions

Is MOTS-C the same as CB4211? No — CB4211 is a related analog developed by a separate company (Cohbar) for its own clinical pipeline. Its Phase 1 human data is an indirect, reasonable safety signal, not direct evidence for MOTS-C itself.

Has MOTS-C actually been tested in human trials? Not for efficacy, as of this writing. The compound’s own direct human trial history doesn’t extend past correlational observational data (lower levels associated with metabolic disease and age). The one interventional Phase 1 program studied a related analog.

Why is cycling considered so important for this compound specifically? Because it works through continuous activation of a single pathway (AMPK), and community consensus — based on that mechanism rather than a specific trial — holds that continuous activation without breaks may produce diminishing returns over time.

Is MOTS-C legal to buy in Canada? It’s sold as a research-use-only compound. See our full Canadian regulatory guide for the general framework that applies to compounds in this category.

Before You Start

A quick checklist to run through before your first dose:

• [ ] Confirmed whether you’re managing diabetes or using glucose-lowering medication, and planned monitoring accordingly
• [ ] Planned your cycling schedule (8–12 weeks on, 4–8 weeks off) before starting, rather than treating continuous use as the default
• [ ] Decided whether your objective is exercise-linked or general metabolic/longevity focused, to guide timing
• [ ] Have a tracking method ready for dose, timing, and observed effects
• [ ] Understand that MOTS-C itself has no completed human efficacy trials, and are comfortable with that tradeoff

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Protocol	Dose	Frequency
Lower dose	1–2mg	Daily to 3x weekly
Standard	5mg	Three times weekly, pre-exercise
Higher range	10mg	Three times weekly

Standard cycle: 8–12 weeks on, 4–8 weeks off.

Where to Go From Here

• The Longevity Compound Group — NAD+ and MOTS-C compared in full
• NAD+: The Complete Guide
• Our Canadian Regulatory Landscape Guide
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.